Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer-Reference-Cited by-同舟云学术

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Published:2024-07-04 Issue:1 Volume:391 Page:44-55
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Vergote Ignace¹,González-Martín Antonio¹,Fujiwara Keiichi¹,Kalbacher Elsa¹,Bagaméri Andrea¹,Ghamande Sharad¹,Lee Jung-Yun¹,Banerjee Susana¹,Maluf Fernando Cotait¹,Lorusso Domenica¹,Yonemori Kan¹,Van Nieuwenhuysen Els¹,Manso Luis¹,Woelber Linn¹,Westermann Anneke¹,Covens Allan¹,Hasegawa Kosei¹,Kim Byoung-Gie¹,Raimondo Miriam¹,Bjurberg Maria¹,Cruz Felipe Melo¹,Angelergues Antoine¹,Cibula David¹,Barraclough Lisa¹,Oaknin Ana¹,Gennigens Christine¹,Nicacio Leo¹,Teng Melinda Siew Leng¹,Whalley Elizabeth¹,Soumaoro Ibrahima¹,Slomovitz Brian M.¹

Affiliation:

1. From Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, and the Belgium and Luxembourg Gynaecological Oncology Group, Leuven (I.V., E.V.N.), and Centre Hospitalier Universitaire de Liège, Liege (C.G.) — all in Belgium; Cancer Center Clínica Universidad de Navarra (A.G.-M.), Hospital Universitario 12 de Octubre (L.M.), and Grupo Español de Investigación en Cáncer de Ovario (GEICO) (A.G.-M.), Madrid, and Gynecologic Cancer Program, Vall d’Hebron Institute of Oncology, Hospital...

Funder

Genmab A/S

Seagen Inc., which was acquired by Pfizer Inc. in Dec 2023

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2313811

Reference19 articles.

1. Recurrent or primary metastatic cervical cancer: current and future treatments

2. National Cancer Institute. SEER cancer stat facts: cervical cancer (https://seer.cancer.gov/statfacts/html/cervix.html).

3. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

4. Survival with Cemiplimab in Recurrent Cervical Cancer

5. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future;Expert Opinion on Drug Metabolism & Toxicology;2024-09-09

2. On the Need for Better Information from Randomized Clinical Trials in Oncology;2024-09-03

3. Surgery-based radiation-free multimodality treatment for locally advanced cervical cancer;Taiwanese Journal of Obstetrics and Gynecology;2024-09

4. Cervical cancer: a new era;International Journal of Gynecologic Cancer;2024-08-07

5. Tisotumab vedotin effective in recurrent cervical cancer;Nature Reviews Clinical Oncology;2024-07-22